Andrx once-daily fexofenadine under development with Sepracor -- SEC registration.
ANDRX ONCE-DAILY FEXOFENADINE WILL BE FIRST BRANDED PRODUCT, the company indicates in a recent registration statement filed with the Securities & Exchange Commission. Under an April 1996 agreement with Sepracor, Andrx will develop a once-daily formulation of fexofenadine (terfenadine carboxylate) and will receive fees and royalties from eventual sales or licensing of the antihistamine. Under the agreement, Sepracor has responsibility for obtaining FDA approval, manufacturing and marketing the once-daily fexofenadine.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth